DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Recommendation of "Hold" by Brokerages

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) have received a consensus rating of "Hold" from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $20.36.

A number of brokerages have commented on XRAY. StockNews.com upgraded shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Robert W. Baird dropped their price target on DENTSPLY SIRONA from $22.00 to $20.00 and set a "neutral" rating on the stock in a research note on Friday, February 28th. Barrington Research increased their price objective on shares of DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an "outperform" rating in a research report on Monday. Wells Fargo & Company lowered their price objective on shares of DENTSPLY SIRONA from $20.00 to $19.00 and set an "equal weight" rating for the company in a research note on Friday, February 28th. Finally, Jefferies Financial Group downgraded DENTSPLY SIRONA from a "buy" rating to a "hold" rating and dropped their price target for the company from $30.00 to $20.00 in a research note on Thursday, January 23rd.

DENTSPLY SIRONA Stock Down 0.9%

Shares of XRAY opened at $16.45 on Thursday. The firm has a market capitalization of $3.28 billion, a P/E ratio of -7.95, a P/E/G ratio of 1.80 and a beta of 0.92. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72. DENTSPLY SIRONA has a 12-month low of $12.16 and a 12-month high of $28.50. The firm has a fifty day moving average price of $14.38 and a 200-day moving average price of $17.48.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping the consensus estimate of $0.29 by $0.14. DENTSPLY SIRONA had a positive return on equity of 12.62% and a negative net margin of 10.59%. The company had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. During the same period last year, the business posted $0.42 EPS. DENTSPLY SIRONA's quarterly revenue was down 7.8% on a year-over-year basis. Equities research analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were issued a $0.16 dividend. The ex-dividend date was Friday, March 28th. This represents a $0.64 dividend on an annualized basis and a yield of 3.89%. DENTSPLY SIRONA's payout ratio is -14.10%.

Insider Buying and Selling at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier bought 15,142 shares of the stock in a transaction on Monday, March 3rd. The shares were bought at an average price of $16.51 per share, with a total value of $249,994.42. Following the purchase, the director now directly owns 81,971 shares in the company, valued at $1,353,341.21. This trade represents a 22.66% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.50% of the stock is owned by corporate insiders.

Institutional Trading of DENTSPLY SIRONA

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of DENTSPLY SIRONA by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier's stock valued at $309,864,000 after buying an additional 557,329 shares during the period. First Eagle Investment Management LLC lifted its stake in DENTSPLY SIRONA by 2.5% during the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier's stock worth $275,218,000 after acquiring an additional 348,532 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in DENTSPLY SIRONA by 11.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after acquiring an additional 1,412,517 shares in the last quarter. Nuance Investments LLC increased its stake in DENTSPLY SIRONA by 25.0% during the fourth quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after purchasing an additional 2,708,097 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its position in DENTSPLY SIRONA by 4.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 12,077,949 shares of the medical instruments supplier's stock valued at $180,445,000 after buying an additional 538,531 shares during the period. Hedge funds and other institutional investors own 95.70% of the company's stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.